Clene Inc. CLNN
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Clene Inc. (CLNN) is a healthcare company listed in the US with a market value of about $56M. In the twelve months to September 30, 2026 it had revenue of $238000 and net income of -$27M, a net margin of -11271.4%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -1% a year, a 5-year average ROIC of -588%.
About Clene
Clene is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $206000 in 2020 to $200000 in 2025, a decline of about 0.6% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 202% over three years (dilution for shareholders). It spends 7006% of revenue on research and development.
Score: 0.4 / 5
Checks passed
- Strong R&D investment or growth above 20%
- ROE above 15%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $238000 | $200000 | $342000 | $654000 | $473000 | $723000 | $206000 | — |
| Net income | -$27M | -$26M | -$39M | -$50M | -$30M | -$10M | -$19M | -$16M |
| Free cash flow | -$17M | -$19M | -$21M | -$31M | -$44M | -$36M | -$19M | -$13M |
| EPS (diluted) | $-2.35 | $-2.65 | $-5.67 | $-9.43 | $-9.20 | $-3.20 | $-22.00 | $-18.60 |
| Net margin | -11271.4% | -13086.5% | -11520.5% | -7569.4% | -6325.2% | -1347.2% | -9357.8% | — |
| ROIC | — | -542.9% | -1945.5% | -113.3% | -187.8% | -150.6% | -156.7% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Clene pay a dividend?
Not currently.
Is Clene a good stock to buy?
We do not give buy or sell advice. Clene scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.